Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 45Carcinoma, Hepatocellular 13Osteosarcoma 8Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Sarcoma, Ewing 6Neuroendocrine Tumors 6Kidney Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Transitional Cell 4Carcinoma, Medullary 4Carcinoma 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Melanoma 3Endometrial Neoplasms 3Adrenocortical Carcinoma 3Wilms Tumor 2Urogenital Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2

Interventions

pembrolizumab 5enfortumab vedotin 3Gemcitabine 3dodecyl maltoside 2Sunitinib 2Cisplatin 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1tucatinib 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1palbociclib 1niraparib 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1cabozantinib 1Valproic Acid 1Urinary Diversion 1Trastuzumab 1Testosterone Propionate 1Standard of Care 1Sirolimus 1Rivaroxaban 1Ringer's acetate 1Radiosurgery 1Radiation Dose Hypofractionation 1Psychiatric Nursing 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Nivolumab 1Multiparametric Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × cabozantinib × 1 year × Clear all
NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡